Editor’s note: This is a developing news story. Please check back soon for updates.
At 12 months in a phase 1/2 trial, the Bimatoprost Drug Pad-IOL System improved IOP, vision and treatment burden in patients with open-angle glaucoma or ocular hypertension with concomitant cataract.
According to a press release from SpyGlass Pharma, 104 patients were randomly assigned 2:1:1 to receive 78 µg Bimatoprost Drug Pad-IOL System (BIM-IOL System) (51 patients) with daily administration of artificial tear drops, 39 µg BIM-IOL System (23 patients) with daily administration of artificial tear drops, or